摘要
类风湿性关节炎是一种常见的消耗人力,社会和经济成本相当大的慢性炎症性和破坏性关节病。它由一个综合征疼痛,滑膜的刚度和对称性炎症(滑膜炎)自由活动的关节如膝关节(动关节)组成。虽然类风湿性关节炎的病因尚不明确,本病的特点是动关节滑膜炎症,滑膜增生和炎性细胞的高潮,通过新生血管巨噬细胞和淋巴细胞。疾病修饰抗风湿药物减缓疾病的进展,并且可引起部分患者病情缓解。甲氨蝶呤是一线治疗药物,但如果患者对这种药物不能耐受,应使用生物制剂。治疗风湿性疾病的生物物质的发展一直伴随着正在进行的健康经济的讨论,这些都是非常有效的实施,但因此,高价药物是风湿性疾病的标准治疗指南。在这种方式中,必须确定更有效的策略。尽管在过去几年里,在类风湿关节炎的众多评论,这方面是在不断的发展和更新,是一个迫切需要纳入类风湿关节炎研究的新进展。本文重点强调了类风湿性关节炎目前的治疗策略的理论基础的发病机制。
关键词: 动物模型,抗风湿药,免疫病理,风湿性关节炎,治疗。
Current Medicinal Chemistry
Title:Update on Therapeutic Approaches for Rheumatoid Arthritis
Volume: 23 Issue: 21
Author(s): Eugénia Nogueira, Andreia Gomes, Ana Preto, Artur Cavaco-Paulo
Affiliation:
关键词: 动物模型,抗风湿药,免疫病理,风湿性关节炎,治疗。
摘要: Rheumatoid arthritis is a common chronic inflammatory and destructive arthropathy that consumes considerable personal, social and economic costs. It consists of a syndrome of pain, stiffness and symmetrical inflammation of the synovial membrane (synovitis) of freely moveable joints such as the knee (diarthrodial joints). Although the etiology of rheumatoid arthritis is unclear, the disease is characterized by inflammation of the synovial lining of diarthrodial joints, high synovial proliferation and an influx of inflammatory cells, macrophages and lymphocytes through angiogenic blood vessels. Diseasemodifying antirheumatic drugs slow disease progression and can induce disease remission in some patients. Methotrexate is the first line therapy, but if patients become intolerant to this drug, biologic agents should be used. The development of biological substances for the treatment of rheumatic conditions has been accompanied by ongoing health economic discussions regarding the implementation of these highly effective, but accordingly, highly priced drugs are the standard treatment guidelines of rheumatic diseases. In this way, more efficient strategies have to be identified. Despite numerous reviews in rheumatoid arthritis in the last years, this area is in constant development and updates are an urgent need to incorporate new advances in rheumatoid arthritis research. This review highlights the immunopathogenesis rationale for the current therapeutic strategies in rheumatoid arthritis.
Export Options
About this article
Cite this article as:
Eugénia Nogueira, Andreia Gomes, Ana Preto, Artur Cavaco-Paulo , Update on Therapeutic Approaches for Rheumatoid Arthritis, Current Medicinal Chemistry 2016; 23 (21) . https://dx.doi.org/10.2174/0929867323666160506125218
DOI https://dx.doi.org/10.2174/0929867323666160506125218 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytotoxicity and Anti-Inflammatory Effects of Polyherbal Formulations, Joint Pain Spl and Rumalaya Forte on Lipopolysaccharide Induced Inflammation in IC-21 Macrophages
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Meloxicam-loaded Phospholipid/solutol® HS15 Based Mixed Nanomicelles: Preparation, Characterization, and in vitro Antioxidant Activity
Pharmaceutical Nanotechnology Licofelone-A Novel Analgesic and Anti-Inflammatory Agent
Current Topics in Medicinal Chemistry Dendritic Cells for Active Anti-Cancer Immunotherapy: Targeting Activation Pathways Through Genetic Modification
Endocrine, Metabolic & Immune Disorders - Drug Targets Cyclodextrin-Based Delivery Systems for Arthritic Diseases: From Development to Experimental Therapeutics
Current Pharmaceutical Design The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
CNS & Neurological Disorders - Drug Targets Pentraxins and Atherosclerosis: The Role of PTX3
Current Pharmaceutical Design Survey of Epstein Barr Virus (EBV) Immunogenic Proteins and their Epitopes: Implications for Vaccine Preparation
Recent Patents on Anti-Infective Drug Discovery The Haywain: Anti-synthetase Antibodies in Patients with Inflammatory Diseases: Targeting Monocytes or Neutrophils?
Current Medicinal Chemistry Targeting miRNAs for Drug Discovery: A New Paradigm
Current Molecular Medicine Etanercept for the Treatment of Dermatological Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Biosimilars Regulation in the United States and FDA Approved Biosimilars from 2015-2018
Applied Clinical Research, Clinical Trials and Regulatory Affairs Tetracyclines: Drugs with Huge Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Novel Self-micro Emulsifying Drug Delivery System for Safe Intramuscular Delivery with Improved Pharmacodynamics and Pharmacokinetics
Current Drug Delivery Analysis of Nucleic Acids and Proteins in Capillary Electrophoresis and Microchip Capillary Electrophoresis Using Polymers as Additives of the Background Electrolytes
Current Analytical Chemistry Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment
Current Drug Targets Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis
Current Rheumatology Reviews Multi-Constituent Cardiovascular Pills (MCCP) - Challenges and Promises of Population-Based Prophylactic Drug Therapy for Prevention of Heart Attack
Current Pharmaceutical Design Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design Eicosanoids in Prevention and Management of Diseases
Current Molecular Medicine